Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events

News

Romark Closes $75 Million Financing

Proceeds of Senior Secured Notes Provide Capital for Expansion of Commercial Organization

TAMPA, Fla. – September 3, 2013 – Romark Laboratories announced today that it has closed a $75 million private senior debt financing, the proceeds of which will be used to expand its sales and marketing organization in the United States and refinance existing debt.

"We are pleased to have completed this financing," said Marc Ayers, President and Chief Executive Officer of Romark. "The new capital will facilitate the expansion of our commercial organization in the United States, paving the way for continued growth of our Alinia® business and the commercial launch of NT-300. Our ability to close this transaction speaks to the strength of our existing business and the opportunity provided by new products in development."

The company sold $75 million of senior secured notes in a syndicated private placement to institutional investors. Morgan Stanley & Co. LLC acted as Sole Placement Agent for the transaction.

About Romark Laboratories

Romark Laboratories, L.C. is a vertically integrated biopharmaceutical company committed to the discovery, development and delivery of innovative small molecule drugs for treating infectious diseases and cancers. The Company markets Alinia® (nitazoxanide) tablets, 500 mg in the United States through a specialty sales force focused on gastroenterologists and primary care physicians.

Romark is developing a class of small molecule drugs called thiazolides. The Company's product, NT-300 (nitazoxanide), is presently undergoing Phase 3 clinical development on a global basis for treatment of acute uncomplicated influenza. The NT-300 development program is being conducted under contract HHSO100201300004C with the U.S. Department of Health and Human Services. Other new drugs from the Company’s platform technology are proposed for treatment of viral diseases and cancers.